Literature DB >> 1968959

Comparison of transmitter amino acid levels in rat globus pallidus and neostriatum during hypoglycemia or after treatment with methionine sulfoximine or gamma-vinyl gamma-aminobutyric acid.

F Fonnum1, R E Paulsen.   

Abstract

The levels of amino acids in globus pallidus, a structure heavily innervated with gamma-aminobutyric acid (GABA)-ergic terminals but few glutamergic terminals, were compared with the levels in neostriatum, a structure richly innervated with glutamergic terminals but intermediate in GABAergic terminals. The level of glutamate in neostriatum was twice as high as in globus pallidus whereas the level of GABA in globus pallidus was three times higher than in neostriatum. The level of aspartate was similar in both regions whereas the level of glutamine was correlated with the level of glutamate. Methionine sulfoximine, a glutamine synthetase inhibitor, reduced the level of glutamine to 10-20% of control in both structures. This reduction was accompanied by the largest decrease in the level of glutamate in neostriatum, indicating that transmitter glutamate turns over more rapidly than other glutamate pools. Likewise, insulin decreased the levels of glutamate and glutamine more in neostriatum than in globus pallidus. gamma-Vinyl GABA increased the level of GABA in globus pallidus more than in neostriatum although the percent increase was largest in neostriatum. Treatment with gamma-vinyl GABA was accompanied by a large reduction in the level of GABA, indicating that a substantial proportion of the glutamine pool is linked to GABA metabolism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968959     DOI: 10.1111/j.1471-4159.1990.tb01956.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Effects of simulated upper gastrointestinal hemorrhage on ammonia and related amino acids in blood and brain of chronic portacaval-shunted rats.

Authors:  S W Olde Damink; C H Dejong; N E Deutz; P B Soeters
Journal:  Metab Brain Dis       Date:  1997-06       Impact factor: 3.584

2.  Regional differences in glutamine synthetase inhibition by L-methionine sulfoximine: a microdialysis study in the rabbit brain.

Authors:  T Böttcher; M Goiny; J Bering; S Domhof; R Nau; U Ungerstedt
Journal:  Exp Brain Res       Date:  2003-03-29       Impact factor: 1.972

Review 3.  In situ measurements of enzyme activities in the brain.

Authors:  P Kugler
Journal:  Histochem J       Date:  1993-05

4.  Effect of glutamine synthesis inhibition with methionine sulfoximine on the nitric oxide-cyclic GMP pathway in the rat striatum treated acutely with ammonia: a microdialysis study.

Authors:  Wojciech Hilgier; Michal Wegrzynowicz; Michal Maczewski; Andrzej Beresewicz; Simo S Oja; Pirjo Saransaari; Jan Albrecht
Journal:  Neurochem Res       Date:  2007-08-29       Impact factor: 3.996

5.  Neuropharmacological and neurobiological relevance of in vivo ¹H-MRS of GABA and glutamate for preclinical drug discovery in mental disorders.

Authors:  Conny F Waschkies; Andreas Bruns; Stephan Müller; Martin Kapps; Edilio Borroni; Markus von Kienlin; Markus Rudin; Basil Künnecke
Journal:  Neuropsychopharmacology       Date:  2014-04-03       Impact factor: 7.853

6.  Gene expression changes in the septum: possible implications for microRNAs in sculpting the maternal brain.

Authors:  Changjiu Zhao; Michael C Saul; Terri Driessen; Stephen C Gammie
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

7.  Genes showing altered expression in the medial preoptic area in the highly social maternal phenotype are related to autism and other disorders with social deficits.

Authors:  Terri M Driessen; Brian E Eisinger; Changjiu Zhao; Sharon A Stevenson; Michael C Saul; Stephen C Gammie
Journal:  BMC Neurosci       Date:  2014-01-14       Impact factor: 3.288

Review 8.  Epilepsy, regulation of brain energy metabolism and neurotransmission.

Authors:  Jean-François Cloix; Tobias Hévor
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.